[go: up one dir, main page]

EA201000867A1 - Новые соединения 2-меркаптоциклопентанкарбоновой кислоты, способ их получения и содержащие их фармацевтические композиции - Google Patents

Новые соединения 2-меркаптоциклопентанкарбоновой кислоты, способ их получения и содержащие их фармацевтические композиции

Info

Publication number
EA201000867A1
EA201000867A1 EA201000867A EA201000867A EA201000867A1 EA 201000867 A1 EA201000867 A1 EA 201000867A1 EA 201000867 A EA201000867 A EA 201000867A EA 201000867 A EA201000867 A EA 201000867A EA 201000867 A1 EA201000867 A1 EA 201000867A1
Authority
EA
Eurasian Patent Office
Prior art keywords
group
mercaptocyclopentankarcarbic
acid
formula
receiving
Prior art date
Application number
EA201000867A
Other languages
English (en)
Other versions
EA017867B1 (ru
Inventor
Филипп Глоанек
Гийом Де-Нантой
Анне-Франсуа Гийюзи
Анне-Франсуа Жийюзи
Тони Вербёрен
Алан Рюпен
Филипп Меннесье
Мари-Одиль Валле
Жан-Шарль Кирьон
Филипп Жюбо
Никола Буар
Original Assignee
Ле Лаборатуар Сервье
Л'Инститю Насьональ Де Сьянс Апплике Де Руен
Ле Сантр Насьональ Де-Ля Решерш Сайнтифик
Л'Юниверсите Де Руен
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье, Л'Инститю Насьональ Де Сьянс Апплике Де Руен, Ле Сантр Насьональ Де-Ля Решерш Сайнтифик, Л'Юниверсите Де Руен filed Critical Ле Лаборатуар Сервье
Publication of EA201000867A1 publication Critical patent/EA201000867A1/ru
Publication of EA017867B1 publication Critical patent/EA017867B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/61—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C327/00—Thiocarboxylic acids
    • C07C327/20—Esters of monothiocarboxylic acids
    • C07C327/32—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C07C327/34—Esters of monothiocarboxylic acids having sulfur atoms of esterified thiocarboxyl groups bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups with amino groups bound to the same hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Соединения формулы (I)в которой: Rпредставляет собой атом водорода или группу формулы COR, или Rпредставляет собой группу формулы (А)Rпредставляет собой группу формулы NRR, или Rпредставляет собой азотсодержащую гетероциклическую группу, группу арила или группу гетероарила, Rпредставляет собой атом водорода или группу алкила, m представляет собой целое число от 1 до 6 включительно, n представляет собой 0, 1 или 2, их оптические изомеры, а также их аддитивные соли с фармацевтически приемлемой кислотой. Лекарственные средства.
EA201000867A 2009-06-26 2010-06-24 Новые соединения 2-меркаптоциклопентанкарбоновой кислоты, способ их получения и содержащие их фармацевтические композиции EA017867B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0903111A FR2947266B1 (fr) 2009-06-26 2009-06-26 Nouveaux derives d'acide 2-mercaptocyclopentanecarboxylique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (2)

Publication Number Publication Date
EA201000867A1 true EA201000867A1 (ru) 2010-12-30
EA017867B1 EA017867B1 (ru) 2013-03-29

Family

ID=41594318

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000867A EA017867B1 (ru) 2009-06-26 2010-06-24 Новые соединения 2-меркаптоциклопентанкарбоновой кислоты, способ их получения и содержащие их фармацевтические композиции

Country Status (28)

Country Link
US (1) US8309341B2 (ru)
EP (1) EP2272826A1 (ru)
JP (1) JP5238757B2 (ru)
KR (1) KR101187394B1 (ru)
CN (1) CN101928241A (ru)
AP (1) AP2010005304A0 (ru)
AR (1) AR078415A1 (ru)
AU (1) AU2010202563A1 (ru)
BR (1) BRPI1001935A2 (ru)
CA (1) CA2707647A1 (ru)
CL (1) CL2010000694A1 (ru)
CO (1) CO6300113A1 (ru)
CR (1) CR11494A (ru)
CU (1) CU20100133A7 (ru)
EA (1) EA017867B1 (ru)
EC (1) ECSP10010292A (ru)
FR (1) FR2947266B1 (ru)
GT (1) GT201000184A (ru)
IL (1) IL206405A0 (ru)
MA (1) MA32340B1 (ru)
MX (1) MX2010007070A (ru)
NI (1) NI201000111A (ru)
NZ (1) NZ586444A (ru)
PE (1) PE20110022A1 (ru)
TW (1) TWI380813B (ru)
UY (1) UY32702A (ru)
WO (1) WO2010149888A1 (ru)
ZA (1) ZA201004398B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3046793B1 (fr) * 2016-01-14 2018-01-05 Les Laboratoires Servier Nouveaux derives de phosphinanes et azaphosphinanes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN109467506B (zh) * 2017-09-07 2021-12-07 江苏瑞科医药科技有限公司 一种取代苯乙酸衍生物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4315031A (en) * 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
US4385062A (en) * 1980-01-09 1983-05-24 Gruppo Lepetit S.P.A. 1-[(-2-Mercaptocycloalkyl)carbonyl]-L-proline derivatives, the process for their manufacture, the intermediates for their synthesis and their use as anti-hypertensive agents
JPS5750955A (en) * 1980-09-12 1982-03-25 Hokko Chem Ind Co Ltd Oxime carbamate derivative and insecticide
JPH0565258A (ja) * 1991-07-03 1993-03-19 Nippon Bayeragrochem Kk 酢酸アニリド誘導体および除草剤
NZ253524A (en) * 1992-05-29 1997-01-29 Procter & Gamble Pharma Sulphur-containing phosphonate derivatives and medicaments (for treating abnormal calcium and phosphate metabolism)
NZ522823A (en) * 2000-08-17 2004-11-26 Pfizer Substituted imidazoles as TAFIa inhibitors
AU2003230698B2 (en) * 2002-03-21 2009-03-26 Bayer Schering Pharma Aktiengesellschaft Plasma carboxypeptidase B inhibitors
WO2004031216A1 (de) * 2002-10-04 2004-04-15 Pentapharm Ag Substrate für tafi (a)
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla

Also Published As

Publication number Publication date
EA017867B1 (ru) 2013-03-29
MX2010007070A (es) 2011-01-05
CO6300113A1 (es) 2011-07-21
WO2010149888A1 (fr) 2010-12-29
MA32340B1 (fr) 2011-06-01
AU2010202563A1 (en) 2011-01-20
GT201000184A (es) 2012-04-30
KR20110000516A (ko) 2011-01-03
AP2010005304A0 (en) 2010-06-30
US20100330064A1 (en) 2010-12-30
CR11494A (es) 2010-09-13
JP2011006416A (ja) 2011-01-13
ZA201004398B (en) 2011-03-30
JP5238757B2 (ja) 2013-07-17
NZ586444A (en) 2011-09-30
UY32702A (es) 2010-12-31
FR2947266A1 (fr) 2010-12-31
TW201105322A (en) 2011-02-16
CA2707647A1 (fr) 2010-12-26
KR101187394B1 (ko) 2012-10-02
BRPI1001935A2 (pt) 2012-03-06
CL2010000694A1 (es) 2011-05-06
PE20110022A1 (es) 2011-02-04
EP2272826A1 (fr) 2011-01-12
FR2947266B1 (fr) 2011-06-17
NI201000111A (es) 2010-12-17
IL206405A0 (en) 2010-12-30
AR078415A1 (es) 2011-11-09
TWI380813B (zh) 2013-01-01
CN101928241A (zh) 2010-12-29
CU20100133A7 (es) 2012-02-15
ECSP10010292A (es) 2011-06-30
US8309341B2 (en) 2012-11-13

Similar Documents

Publication Publication Date Title
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
RU2014140735A (ru) ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201490445A1 (ru) Циклопропанаминовое соединение
CA2875877C (en) Syk inhibitors
EA201490726A1 (ru) Фармацевтические соединения для применения в терапии инфекции clostridium difficile
EA201071329A1 (ru) Диамидные производные адамантана и их применение
BRPI1009333B8 (pt) compostos inibidores de beta-secretase, seus usos, bem como composição farmacêutica
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
AR082499A1 (es) Compuestos utiles para trastornos del sistema nervioso, inflamatorios, estomacales y como analgesicos
EA201270646A1 (ru) Ингибиторы глюкозилцерамидсинтазы
EA200801828A2 (ru) Соединения 1,2,4,5-тетрагидро-3h-бензазепина, способ их получения и фармацевтические композиции, содержащие эти соединения
AR082968A1 (es) Inhibidores biciclicos de notum pectinacetilesterasa y una composicion farmaceutica en base al compuesto
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
PH12015502429A1 (en) Dicarboxylic acid compound
EA201270302A1 (ru) Безводные формы производных пиридина
EA201190269A1 (ru) 2'-фторарабинонуклеозиды и их применение
EA201390374A1 (ru) Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
RU2014131017A (ru) Хиназолиноновые производные в качестве ингибиторов hcv
EA200900481A1 (ru) Новые соединения индола, способ их получения и фармацевтические композиции, которые их содержат
EA201000867A1 (ru) Новые соединения 2-меркаптоциклопентанкарбоновой кислоты, способ их получения и содержащие их фармацевтические композиции
EA201200267A1 (ru) Новые соединения дигидрооксазолобензодиазепинона, способ их получения и фармацевтические композиции, их содержащие
EA200601248A1 (ru) Новые многократно замещённые соединения 1,1-пиридилоксициклопропанамина, способ их получения и фармацевтические композиции, которые их содержат
EA201101175A1 (ru) Фармацевтические комбинации 5-фторурацила и производных 1,4-дигидропиридина и их применение для лечения рака
EA201891599A1 (ru) Новые производные фосфинанов и азафосфинанов, способ их получения и содержащие их фармацевтические композиции
EA201001042A1 (ru) Новые пиперидиновые соединения, способ их получения и фармацевтические композиции, содержащие их

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU